Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

Small Molecule CMO and CDMO Companies, Market Entry and Expansion Strategies

Date : 27 February 2026

Top Companies in the Small Molecule CMO and CDMO Market and Their Offerings

Companies Headquarters Solutions
Lonza Basel, Switzerland Full-lifecycle CDMO services
Thermo Fisher Scientific Waltham, U.S. End-to-end development services
Catalent Somerset, U.S. Provides soft gel technologies and clinical supply services
WuXi AppTec Shanghai, China Comprehensive chemistry services
Samsung Biologics Incheon, South Korea Offer advanced chemical synthesis and integrated manufacturing
Piramal Pharma Solutions Mumbai, India Integrated services
Cambrex East Rutherford, U.S. Provides small-molecule API development, generic APIs, and specialized drug substance manufacturing
Recipharm Stockholm, Sweden High volume oral solid production and inhalation drug delivery expertise
Siegfried Holding Zofingen, Switzerland Complex chemical synthesis, sterile filling, and finished dosage forms of small molecule injectables
Euroapi Paris, France Developed APIs and intermediates of generic and specialty molecules

Market Value Chain Analysis

R&D

  • The R&D of the small molecule CMO and CDMO focuses on the adoption of green chemistry, continuous manufacturing, and AI-driven optimization to accelerate drug timelines.
  • Key players: Lonza, WuXi AppTec, Thermo Fisher Scientific.

Clinical Trials and Regulatory Approvals

  • The compliance with the cGMP, batch-to-batch consistency, and impurity profiling are evaluated in the clinical trials and regulatory approvals of the small molecule CMO and CDMO.
  • Key players: Lonza, Catalent, Thermo Fisher Scientific.

Patient Support and Services

  • Patient-centric dosage design, such as pediatric formulations and dose-titration packaging, is offered in the patient support and services of the small-molecule CMO and CDMO.
  • Key players: Lonza, Catalent, Thermo Fisher Scientific.

Market Growth

The global small molecule CMO and CDMO market size was estimated at USD 75.8 billion in 2025 and is predicted to increase from USD 79.7 billion in 2026 to approximately USD 125.13 billion by 2035, expanding at a CAGR of 5.14% from 2026 to 2035.

Small Molecule CMO and CDMO Market Size is USD 79.7 Billion in 2026.

What are the Recent Developments in the Market?

  • In February 2026, 100% of the shares of Recipharm Israel Ltd. were acquired by Scinai Immunotherapeutics Ltd., which will expand its capabilities, commercial positioning, and manufacturing footprint, solidifying its CDMO platform, promoting the development of small molecules, recombinant proteins, peptides, oligonucleotides, and antibodies.
  • In May 2025, a new proprietary Design2Optimize platform focused on enhancing the process development and manufacturing of small molecule APIs was launched by Lonza, which will offer optimal conditions for experiments.

One place. One platform. Complete visibility into the Small Molecule CMO and CDMO Market - Access the Dashboard

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales